Articles By Jack Cush, MD
Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis
Claims data analysis of 4245 psoriatic arthritis patients on TNF inhibitors showed both higher than expected durations of noncompliance and higher than label dosing - all at an increased cost.
Read Article
ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use
The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women. The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.
Read Article
CDC Shows a 40% Lifetime Risk of Symptomatic Hand Osteoarthritis
Qin and colleagues have published in Arthritis & Rheumatology that 40% of people will be affected by symptomatic osteoarthritis in at least one hand. (Citation source: http://buff.ly/2qTUscZ)
Read Article
Increased Comorbidities in Rheumatoid Arthritis
A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.
Read Article
The RheumNow Week in Review – 5 May 2017
Dr Jack Cush reviews highlights from the news last week on RheumNow.com:
Read Article
US Drug Spending Will Rise Steadily Thru 2021
Reuters has reported that U.S.spending on prescription drugs in 2016 increased by 5.8 percent over 2015 levels to $450 billion based on list prices, and by 4.8 percent to $323 billion when adjusted for discounts and rebates.
Read Article
Tofacitinib Effective in Ulcerative Colitis
Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, and psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).
Read Article
Enthesitis-Related Arthritis in Children
Enthesitis-related arthritis (ERA) is an emerging subset of juvenile idiopathic arthritis (JIA) recognized for its distinctive clinical characteristics.
Read Article
Will Restricting Pharmaceutical Sales Rep Access Result in Healthcare Savings?
A current JAMA report shows that the implementation of policies at academic medical centers that restricted pharmaceutical sales representative (PSR) detailing was associated with modest but significant reductions in prescribing of detailed drugs across six of eight major drug classes; however, c
Read Article
NEJM: Adalimumab and MTX Effective in JIA Uveitis
The NEJM has published the results of a randomized, placebo-controlled trial showing adalimumab and methotrexate is effective in reducing ocular flares in juvenile idiopathic arthritis with uveitis.
Read Article
